Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
PhoreMost Ltd, a biopharmaceutical company and University of Cambridge spin-out founded to identify new druggable targets for cancer and other unmet diseases, announced that it has raised £2.5 million in seed funding from Cambridge-based investors: Jonathan Milner, Amadeus Capital, Sunil Shah and Prashant Shah (O2H Ventures), Cambridge Enterprise, and Dr Chris Torrance, PhoreMost’s CEO.
7 April 2015Read in full
Enval’s pioneering technology will provide the recycling solution for a project to assess the feasibility of including flexible laminate packaging, such as food and drink pouches, pet food pouches and toothpaste tubes, in existing household recycling schemes.
23 March 2015Read in full
University of Cambridge spin-out XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab, has been acquired by Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Financial terms of the transaction have not been disclosed
19 March 2015Read in full
Cambridge Enterprise portfolio company Sphere Fluidics has been named one of the UK's top 50 disruptive SMEs by Real Business.
9 March 2015Read in full
University spin-out ilumink has been acquired by leading industrial technology specialist Tracerco, part of the Johnson Matthey group.
6 March 2015Read in full
A new, automated cleaning system for geological samples that simplifies their preparation and improves sample reliability has been developed by a team of University of Cambridge researchers.
19 February 2015Read in full
Dr Paul J. Seabright, Head of Cambridge Enterprise (CE) Consultancy Services, has been appointed the University knowledge transfer company’s new Deputy Director. He replaces Dr Richard Jennings, who will retire from the post in March.
3 February 2015Read in full
Dr Geraldine Rodgers, an early, driving force of University investment support for spin-out companies, has died from lung cancer. She was 66.
27 January 2015Read in full
Dr Richard Jennings, a UK pioneer in the field of academic knowledge transfer, will in March step down as Deputy Director of Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge.
21 January 2015Read in full